James Legg

James is currently SVP Research and Early Development at Mestag Therapeutics, a biotechnology company based in Cambridge UK working on fibroblast-immune interactions in Oncology and Inflammatory disease. Prior to Mestag, James held a similar role at Crescendo Biologics with responsibility for the immuno-oncology portfolio from research into preclinical development. James has over 20 years’ experience in biologics drug discovery and has been responsible for the successful progression of multiple oncology biologics programmes. James was a member of the oncology leadership team at MedImmune, the biologics arm of AstraZeneca, and held key scientific positions at Cambridge Antibody Technology. James has a BSc in applied biology from Bath University, a PhD in molecular cell biology from Imperial College, London and undertook post-doctoral research with Fiona Watt at Imperial Cancer Research Fund (now CRUK) in London.